Treatment of Immune-Mediated Extraintestinal Manifestations of Inflammatory Bowel Disease with Infliximab

Gastroenterology Clinics of North America

Volumn 35, Issue 4, 2006, Pages 883-893

  Barrie, Arthur ^a   Plevy, Scott ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; RITUXIMAB;

ARTICLE; CELL STIMULATION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; ENTERITIS; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL PRACTICE; MORBIDITY; PATIENT CARE; PREDICTION; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; EYE DISEASES; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; JOINT DISEASES; SKIN DISEASES;

EID: 33751255051     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2006.09.001     Document Type: Article

References (75)

1. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
2. Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
3. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
4. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
5. Targan S.R., Hanauer S.B., van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 (1997) 1029-1035
6. Das K.M. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci 44 (1999) 1-13
7. Juillerat P., Mottet C., Froehlich F., et al. Extraintestinal manifestations of Crohn's disease. Digestion 71 (2005) 31-36
8. Monsen U., Sorstad J., Hellers G., et al. Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol 85 (1990) 711-716
9. Rankin G.B., Watts H.D., Melnyk C.S., et al. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 77 (1979) 914-920
10. Greenstein A.J., Janowitz H.D., and Sachar D.B. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 55 (1976) 401-412
11. Su C.G., Judge T.A., and Lichtenstein G.R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 31 (2002) 307-327
12. Bernstein C.N., Blanchard J.F., Rawsthorne P., and Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 96 (2001) 1116-1122
13. Veloso F.T., Carvalho J., and Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 23 (1996) 29-34
14. De Vos M. Joint involvement in inflammatory bowel disease. Aliment Pharmacol Ther 20 Suppl 4 (2004) 36-42
15. Van Bodegraven A.A., and Pena A.S. Treatment of extraintestinal manifestations in inflammatory bowel disease. Curr Treat Options Gastroenterol 6 (2003) 201-212
16. den Broeder A.A., Joosten L.A., Saxne T., et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 61 (2002) 311-318
17. Elliott M.J., Maini R.N., Feldmann M., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344 (1994) 1105-1110
18. Maini R., St Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (1999) 1932-1939
19. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 (2006) 323-333 quiz 591
20. Weinblatt M.E., Kremer J.M., Bankhurst A.D., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340 (1999) 253-259
21. Sandborn W.J., Hanauer S.B., Katz S., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 (2001) 1088-1094
22. Papachristou G.I., and Plevy S. Novel biologics in inflammatory bowel disease. Gastroenterol Clin North Am 33 (2004) 251-269 [ix]
23. Hochberg M.C., Lebwohl M.G., Plevy S.E., et al. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 34 (2005) 819-836
24. Bernstein C.N., Wajda A., and Blanchard J.F. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 129 (2005) 827-836
25. Toussirot E., and Wendling D. Crohn's disease associated with seropositive rheumatoid arthritis. Clin Exp Rheumatol 15 (1997) 307-311
26. Kaufman I., Caspi D., Yeshurun D., et al. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int 25 (2005) 406-410
27. Rispo A., Scarpa R., Di Girolamo E., et al. Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. Scand J Rheumatol 34 (2005) 387-391
28. Van den Bosch F., Kruithof E., De Vos M., et al. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 356 (2000) 1821-1822
29. Van den Bosch F., Kruithof E., Baeten D., et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 59 (2000) 428-433
30. Van Den Bosch F., Kruithof E., Baeten D., et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 46 (2002) 755-765
31. Kruithof E., Van den Bosch F., Baeten D., et al. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 61 (2002) 207-212
32. Collantes-Estevez E., Munoz-Villanueva M.C., Canete-Crespillo J.D., et al. Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study. Ann Rheum Dis 62 (2003) 1239-1240
33. Davis Jr. J.C. Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis. Semin Arthritis Rheum 34 (2005) 668-677
34. Brandt J., Haibel H., Cornely D., et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43 (2000) 1346-1352
35. Breban M., Vignon E., Claudepierre P., et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 41 (2002) 1280-1285
36. Braun J., Brandt J., Listing J., et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359 (2002) 1187-1193
37. Braun J., Brandt J., Listing J., et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64 (2005) 229-234
38. Herfarth H., Obermeier F., Andus T., et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol 97 (2002) 2688-2690
39. Generini S., Giacomelli R., Fedi R., et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 63 (2004) 1664-1669
40. Tavarela Veloso F. Review article: skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther 20 Suppl 4 (2004) 50-53
41. Trost L.B., and McDonnell J.K. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 81 (2005) 580-585
42. Ljung T., Staun M., Grove O., et al. Pyoderma gangrenosum associated with Crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol 37 (2002) 1108-1110
43. Mimouni D., Anhalt G.J., Kouba D.J., et al. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol 148 (2003) 813-816
44. Reichrath J., Bens G., Bonowitz A., et al. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 53 (2005) 273-283
45. Sapienza M.S., Cohen S., and Dimarino A.J. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Dig Dis Sci 49 (2004) 1454-1457
46. Tan M.H., Gordon M., Lebwohl O., et al. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 137 (2001) 930-933
47. Triantafillidis J.K., Cheracakis P., Sklavaina M., et al. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum. Scand J Gastroenterol 37 (2002) 863-865
48. Regueiro M., Valentine J., Plevy S., Fleisher M.R., et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 98 (2003) 1821-1826
49. Brooklyn T.N., Dunnill G.S., Shetty A., et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double-blind placebo-controlled trial. Gut (2005)
50. Kugathasan S., Miranda A., Nocton J., et al. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 37 (2003) 150-154
51. Bens G., Laharie D., Beylot-Barry M., et al. Successful treatment with infliximab and methotrexate of pyostomatitis vegetans associated with Crohn's disease. Br J Dermatol 149 (2003) 181-184
52. Foster E.N., Nguyen K.K., Sheikh R.A., et al. Crohn's disease associated with Sweet's syndrome and Sjogren's syndrome treated with infliximab. Clin Dev Immunol 12 (2005) 145-149
53. Konrad A., and Seibold F. Response of cutaneous Crohn's disease to infliximab and methotrexate. Dig Liver Dis 35 (2003) 351-356
54. Gottlieb A.B., Evans R., Li S., et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51 (2004) 534-542
55. Hale S., and Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine (2006)
56. Joseph A., Raj D., Dua H.S., et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 110 (2003) 1449-1453
57. Lindstedt E.W., Baarsma G.S., Kuijpers R.W., et al. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 89 (2005) 533-536
58. Rajaraman R.T., Kimura Y., Li S., et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 113 (2006) 308-314
59. Sfikakis P.P., Theodossiadis P.G., Katsiari C.G., et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 358 (2001) 295-296
60. Fries W., Giofre M.R., Catanoso M., et al. Treatment of acute uveitis associated with Crohn's disease and sacroiliitis with infliximab. Am J Gastroenterol 97 (2002) 499-500
61. Murphy C.C., Ayliffe W.H., Booth A., et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111 (2004) 352-356
62. Saurenmann R.K., Levin A.V., Rose J.B., et al. Tumour necrosis factor {alpha} inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) (2006)
63. Kahn P., Weiss M., Imundo L.F., et al. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology (2006)
64. Braun J., Baraliakos X., Listing J., et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52 (2005) 2447-2451
65. Suhler E.B., Smith J.R., Wertheim M.S., et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 123 (2005) 903-912
66. Silbermintz A., Krishnan S., Banquet A., et al. Granulomatous pneumonitis, sclerosing cholangitis, and pancreatitis in a child with Crohn disease: response to infliximab. J Pediatr Gastroenterol Nutr 42 (2006) 324-326
67. Germano V., Picchianti Diamanti A., Baccano G., et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 64 (2005) 1519-1520
68. Tobon G.J., Canas C., Jaller J.J., et al. Serious liver disease induced by infliximab. Clin Rheumatol (2006)
69. Bouma G., and Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3 (2003) 521-533
70. Mielants H., De Keyser F., Baeten D., et al. Gut inflammation in the spondyloarthropathies. Curr Rheumatol Rep 7 (2005) 188-194
71. Demetter P., Van Huysse J.A., De Keyser F., et al. Increase in lymphoid follicles and leukocyte adhesion molecules emphasizes a role for the gut in spondyloarthropathy pathogenesis. J Pathol 198 (2002) 517-522
72. Baeten D., Demetter P., Cuvelier C.A., et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol 196 (2002) 343-350
73. Schreiber S., Rutgeerts P., Fedorak R.N., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129 (2005) 807-818
74. Edwards J.C., and Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6 (2006) 394-403
75. Genovese M.C., Becker J.C., Schiff M., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353 (2005) 1114-1123